𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ascomycin macrolactam SDZ ASM 981: A new option for treatment of inflammatory skin diseases

✍ Scribed by A. Stütz; M. Graeber; M. Grassberger; F. Kalthoff; J.G. Meingassner

Book ID
118605094
Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
117 KB
Volume
11
Category
Article
ISSN
0926-9959

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The new topical ascomycin derivative SDZ
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study
✍ C. Queille-Roussel; C. Paul; L. Duteil; M-C. Lefebvre; G. Rapatz; M. Zagula; J-P 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 515 KB

## Background: Sdz asm 981 is a selective inhibitor of inflammatory cytokines released from t lymphocytes and mast cells, which has been developed for the treatment of inflammatory skin diseases. ## Objectives: In the present study, the atrophogenic potential of sdz asm 981 1% cream in humans was